derivative showed the highest activity among the new compounds and was comparable to that of TOC-502~4). Encouraged by the favorable results from the benzothiopyrans as substituents of vinyl-thio linkage then we have focused our effort on the synthesis of heterocyclicfused thiopyrans to obtain more effective compounds against MRSAand VRE. In this paper, we describe the synthesis and antibacterial activity of these new 3-heterocyclic-fused thiopyranylthiovinyl cephalosporins represented by formula I (Fig. 1 ).
Chemi stry
The synthetic routes employed for these cephems are similar to those reported in the previous paper1}. The required heterocyclic-fused thiopyranylmercaptans (III) were all new except 2-mercapto-4-oxo-4//-lthiopyrano [2,3-b] 
used in the synthesis of compound8, and these were prepared by the method of Dunn5) or Anderson-McKay6).
The typical procedure is shown in the Scheme 1.
Reaction of vinyltriflate (II), a small excess of mercaptan (III) and 0.8 equiv. of ethyl di-isopropylamine in N,Ndimethylformamide at room temperature afforded thiopyranylthiovinyl cephem (IV). 7-Protecting group of IV was removed by treatment with /?-toluenesulfonic acid to give amine (V), which was coupled with thiophene-2-acetic acid (VI) using DCC to afford the 7-thienylacetamido cephem. This protected cephem was treated with TFAin the presence of anisole to give 7j3-
acid (1) used as standard test organisms in this study. The MRSA (27 strains) used in this study were isolated from clinical specimens in Juntendo University Hospital in Japan. Table 1 shows the antibacterial activities of 7-thienylacetamido-3-heterocyclic-fused thiopyran derivatives. All these compounds except compound3 were highly active against MRSA and VRE. These compoundswere ineffective against Gram-negative bacteria such as E. coli and P. aeruginosa while, hydroxyimino aminothiazole derivatives such as compounds 10 and ll showed activity against E. coli as indicated in Table 2 . Hence, 7-substituent is supposed to be a key factor to govern the activity against E. coli. Among these compounds, thiophene-fused derivatives (1, 2 and 6) were 2-fold more active against MRSAthan HMRZ-4and TOC-50, especially the bromosubstituted compound 2 was fairly active against VRE. By reason that compound3 was not active against both MRSA and VRE, it was suggested that the introduction of bulky substituents at C-3 position of thiopyran ring resulted in the reduction of the antibacterial activity against resistant bacteria. In comparison betweenthiophene-fused derivative (1) and furan-fused derivative (5) on the activity, compound 1 was 4-fold more active against MRSA.The anti-MRSA and anti-VRE activities of pyridine-or pyrazine-fused derivatives (8 and 9) were moderate in comparison with compound1, but the anti-Staphylococcus aureus activity was superior in these compounds. Table 2 shows the effect of the side chain (R) at C-7 position of cephem on the antibacterial activity against MRSAand VRE. Hydroxyimino aminothiazole derivative (10) reduced the activity against MRSA and VRE in comparison with thiophene derivative (1). But chlorosubstituted aminothiazole derivative (ll) showed an excellent antibacterial activity against MRSAand VRE.
It seems that introduction of chloro substituent on aminothiazole is very effective to enhance the activity against these resistant bacteria. Table 3 shows the effect of the linkage attached to thiopyrane at C-3 position of cephem. Vinyl-thio derivative (1) was 32-fold more active against MRSAand 16-fold more active against VREthan thiomethyl derivative (12). Compound1 and 12 were both active against S. aureus. It seems that the ability of electron transfer on linkage between cephemring and external heteroeyclic ring is very important for good activity against resistant Gram-positive bacteria.
In conclusion we found that the introduction of heterocyclic-fused thiopyrane linked vinylthio at C-3 position of cephem enhanced the anti-MRSA and anti-VRE activities.
Among these compounds, we obtained HMRZ-23 (1), HMRZ-40 (2), and having higher anti-MRSA and anti-VRE activity than those of nomoxef (FMOX) and TOC-50. Table 2 . In vitro antibacterial activity (MIC, /ug/ml) of 7-substituted-3-thienothiopyranyl-thiovinyl derivatives. Table 3 . Effect of the linkage attached to thienothiopyrane.
